Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells

F. E. Bertrand(East Carolina University), Linda S. Steelman(East Carolina University), William H. Chappell(East Carolina University), Stephen L. Abrams(East Carolina University), J G Shelton(East Carolina University), Edmond R. White(East Carolina University), Dale L. Ludwig, James A. McCubrey(East Carolina University)
Leukemia
April 27, 2006
10.1038/sj.leu.2404217
Cited by 77

Abstract

Related Papers

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
Ki Y. Chung, Jinru Shia, Nancy E. Kemeny et al.|Journal of Clinical Oncology|2005|1.1k
Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells
Rita Nahta, Linda X.H. Yuan, Bing Zhang et al.|Cancer Research|2005|800
The IGF‐1 receptor in cancer biology
Renato Baserga, Francesca Peruzzi, Krysztof Reiss|International Journal of Cancer|2003|644
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
Constantine S. Mitsiades, Nicholas Mitsiades, Ciaran J. McMullan et al.|Cancer Cell|2004|610
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
Bruce D. Cohen, Deborah A. Baker, Catherine Soderstrom et al.|Clinical Cancer Research|2005|361